openPR Logo
Press release

Pulmonary Drug Delivery Market Sales Revenue Clinical Trials Pipeline Report

07-04-2017 07:13 AM CET | Health & Medicine

Press release from: Kuick Resarch

Pulmonary Drug Delivery Market Sales Revenue Clinical Trials

The demand for new and innovative drug delivery systems has been on a rising trend with the pharmaceutical companies concentrating on developing innovative methods for this area. It is the result of these continued efforts, which have led to the ever rising popularity of pulmonary drug delivery methods across the globe. Pulmonary drug delivery system uses the respiratory tract to deliver drugs into the lungs in order to treat diseases such as asthma, COPD and cystic fibrosis. This market has been attracting significant investments by the pharma companies with relation to development of novel treatment methods.

Download Report:

https://www.kuickresearch.com/report-Pulmonary-Drug-Delivery-Market-&-Clinical-Pipeline-Insight.php

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

"Pulmonary Drug Delivery Market & Clinical Pipeline Insight" Table of Contents

1. Introduction to Pulmonary Drug Delivery

2. Pulmonary Drug Delivery Mechanism
2.1 Segments of Pulmonary Drug Delivery System
2.2 Mechanisms of Drug Delivery

3. Why Need for Pulmonary Drug Delivery?

4. Pulmonary Drug Delivery Market Outlook
4.1 Market Overview
4.2 Clinical Pipeline Analysis

5. Pulmonary Drug Delivery Market Dynamics
5.1 Favorable Market Drivers
5.2 Key Issues to be Discussed

6. Future of Pulmonary Drug Delivery Market

7. Pulmonary Drug Clinical Insight by Phase, Country & Target Indication
7.1 Unknown Phase
7.2 Research
7.3 Preclinical
7.4 Clinical
7.5 Phase I
7.6 Phase I/II
7.7 Phase II
7.8 Phase II/III
7.9 Phase III
7.10 Preregistration
7.11 Registered

8. Marketed Pulmonary Drug Profiles

9. Suspended & Discontinued Pulmonary Drug Profiles
9.1 No Development Reported
9.2 Discontinued
9.3 Market Withdrawal
9.4 Suspended

10. Competitive Landscape
10.1 Allergan Inc. (MAP Pharmaceuticals)
10.2 AstraZeneca (Pearl Therapeutics)
10.3 Bayer HealthCare Pharmaceuticals
10.4 Boehringer Ingelheim
10.5 Gilead Sciences
10.6 Merck & Co
10.7 Teva Pharmaceutical (Microdose Therapeutx)
10.8 Novartis
10.9 Pfizer
10.10 Vectura Group

Figure 1-1: Drug Delivery Methods
Figure 1-2: Evolution Timeline of Pulmonary Drug Delivery Method
Figure 2-1: Segments of Pulmonary Drug Delivery System
Figure 4-1: Global Pulmonary Drug Delivery Market (US$ Billion), 2013-2018
Figure 4-2: Market Segmentation of Pulmonary Drug Delivery
Figure 4-3: Pulmonary Drugs in Clinical Trial by Phase (%), 2014
Figure 4-4: Number of Pulmonary Drugs in Clinical Trial by Phase, 2014
Figure 4-5: No Development Pulmonary Drugs in Clinical Trial by Phase (%), 2014
Figure 4-6: No Development Pulmonary Drugs in Clinical Trial by Phase (%), 2014
Figure 4-7: Discontinued Pulmonary Drugs in Clinical Trial by Phase (%), 2014
Figure 4-8: Discontinued Pulmonary Drugs in Clinical Trial by Phase (%), 2014
Figure 4-9: Suspended Pulmonary Drugs in Clinical Trial by Phase (%), 2014
Figure 4-10: Suspended Pulmonary Drugs in Clinical Trial by Phase (%), 2014

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pulmonary Drug Delivery Market Sales Revenue Clinical Trials Pipeline Report here

News-ID: 606840 • Views: 214

More Releases from Kuick Resarch

Global LAG 3 Inhibitor Clinical Trials and Market Opportunity Insight 2028
Global LAG 3 Inhibitor Clinical Trials and Market Opportunity Insight 2028 Report Highlights: * Global LAG 3 Inhibitors Market Dynamics * Clinical Approaches to Target LAG 3 Inhibitors * Number of LAG 3 Inhibitors Drug In Trials * LAG 3 Inhibitors Approved Patent Insight * LAG 3 Inhibitors Trials By Phase, Company, Country, Indication * Company Agreement/Partnership/Deals For Ongoing Trials * LAG-3 Targeted Approach in Cancer Therapy * Therapeutic Approaches for Novel LAG-3 Targeted Therapy * Global LAG 3
US Cancer Antibodies Market, Drug Sales, Patent and Clinical Trials Outlook 2028
US Cancer Antibodies Market, Drug Sales, Patent and Clinical Trials Outlook 2028 Report Highlights: * US Cancer Antibodies Market Opportunity: > US$ 85 Billion by 2028 * US Cancer Antibodies Market To Witness More Than 200% Absolute Growth * Current and Future market Projections by Drugs and Therapeutic Class * Clinical Trials Insight On by Company, Indication, Patient Segment and Phase * Immune Checkpoint Inhibitors Dominating The Antibodies Sales: > 15 Billion In 2021 * Insight
Global Transdermal Patch Market, Dosage, Price and Clinical Trials Insight 2028
Global Transdermal Patch Market, Dosage, Price and Clinical Trials Insight 2028 Report Highlights: * Research Methodology * Global and Regional Transdermal Path Market Outlook * Global Transdermal Patch Market Opportunity > USD 20 Billion * Clinical Trials Insight By Company, Indication, Drug Molecule and Phase * Comprehensive Insight On 60 Transdermal Patch Available Commercially * Comprehensive Insight On 80 Transdermal Patch In Clinical Trials By Phase * Transdermal Patch Dosage and Price Availability By Indication * Competitive Landscape
Global Cancer Antibody Drug Conjugate Market, Price, Dosage and Clinical Trials …
Global Cancer Antibody Drug Conjugate Market, Drug Sales, Price, and Clinical Trials Insight 2028 Report Highlights: * Global Cancer Antibody Drug Conjugate Market Opportunity > USD 25 Billion * Global Market Sales Trends and Market Forecast Till 2028 * Clinical Insight On 18 Approved Cancer Antibody Drug Conjugates * Dosage, Price and Patent Insight On 18 Cancer Antibody Drug Conjugate * Quarterly and Yearly Drug Sales Insight and Forecast Till 2028 * Clinical Insight On More

All 5 Releases


More Releases for Drug

Biologics Drug Discovery Market
2019-2025 Biologics Drug Discovery Market Report with Depth Analysis The biologics drug discovery involves target identification, hit-to-lead stage, lead identification and optimization. The report presents a comprehensive overview, market size, shares, and growth opportunities of Biologics Drug Discovery market by product type, application, key manufacturers and key regions. Request For Free report Sample -https://www.reportsmonitor.com/request_sample/306320 Scope of the Report: Furthermore, Biologics Drug Discovery Market report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers or
Opioid Antagonist Drug Market
The global market has been prognosticated to earn demand from popular types of products such as external use, oral and applications such as household and hospital. The Company has made available another publication in its Healthcare archive of market intelligence reports, which is titled “Global Opioid Antagonist Drug Market Research Report 2018.” While the threat of substitutes and technological risks could have an unfavorable impact on the global market, potential
Drug and cosmetics
Drug and Cosmetics Conferences regards each one of the individuals to go to the On “Drug and Cosmetics” amidst October 17-October 18, 2018 in Toronto, Canada which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops. Drug and Cosmetics Congress is one of the meetings and conferences which will be visited by all the prestigious cosmetologists, Scientists, fiery inspectors, postgraduates, affiliations, business meanders under a solitary rooftop. DRug and cosmetics BLESSY MATHEW Program
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning